PHILADELPHIA — Edward B. Lee, MD, PhD, an assistant professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, has received a three-year Clinical Scientist Development Award (CSDA) for $486,000 from the Doris Duke Charitable Foundation to support his research in frontotemporal lobar degeneration and amyotrophic lateral sclerosis (ALS).
Lee heads the Translational Neuropathology Research Laboratory, which aims to understand the root causes of neurodegenerative diseases to develop specific disease-modifying therapies. The lab employs an interdisciplinary approach to address the mechanisms of neurodegeneration, using and developing such cutting-edge techniques as high-resolution, multi-spectral, 3-dimensional confocal imaging and next-generation sequencing.
This award will allow Lee to study a mutation in the C9orf72 gene, the most common genetic cause of frontotemporal degeneration and ALS. With collaborators at the Center for Neurodegenerative Disease Research, the ALS Center at Pennsylvania Hospital, and the PENN FTD Center, Lee will determine how epigenetic modifications of C9orf72 affect disease pathogenesis.
Lee earned his medical degree and a doctorate in 2005 from the Perelman School of Medicine and completed his Anatomic Pathology residency and his Neuropathology fellowship at the Hospital of the University of Pennsylvania. He is also the recipient of the 2012 Excellence in Science Award from the American Society for Investigative Pathology.
The CSDA funds physician-scientists who are forming their own research teams and allows them to dedicate 75 percent of their professional time to clinical research. Since 1998, the Doris Duke Foundation has awarded 235 CSDAs, with 17 recipients this year.
To learn more about the CSDA, visit www.ddcf.org.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.